"A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer." by Reshma Mahtani

Article

A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer.

Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting (2013)

Reshma Mahtani, Baptist Health South Florida
Joerg Engel
Andrew V. Schally
Stephanie Seitz
Olaf Ortmann
Stefan Gluck, University of Miami
Charles L. Vogel, University of Miami
Alberto J. Montero, Cleveland Clinic

Link

Disciplines

Medicine and Health Sciences

Publication Date

2013

Citation Information

Reshma Mahtani, Joerg Engel, Andrew V. Schally, Stephanie Seitz, et al.. "A Randomized, Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple-negative (ER/PR/HER2-negative) LHRH-R Positive Metastatic Breast Cancer." Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting Vol. 29 Iss. Suppl. (2013)
Available at: http://works.bepress.com/reshma-mahtani/11/